Monograph Details
|
|
Immune System
> Immunization
|
|
COMVAX |
| Manufacturer |
|
Merck & Co., Inc. |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Hib (PRP-OMP) + HB. |
| Generic Name |
|
Haemophilus b conjugate 7.5micrograms (meningococcal protein conjugate 125micrograms) + hepatitis B surface antigen (HBsAg) (recombinant) 5micrograms; per 0.5mL; susp for IM inj; aluminum hydroxide adsorbed; preservative-free. |
| Indications |
|
Vaccination against H. influenzae type b and hepatitis B in infants 6 weeks to 15 months of age born of HBsAg-negative mothers. |
| Children |
|
<6 weeks: Not recommended. 6 weeks to 15 months: Give IM in anterolateral thigh. Previously unvaccinated, or one previous dose of hepatitis B vaccine: one 0.5mL dose at 2, 4, and 12–15 months of age. Others: individualize (see literature). |
| Precautions |
|
Immunodeficiency/ suppression or malignancy: may get suboptimal response. Have epinephrine (1:1000) inj available. Delay administration in acute febrile illness. Pregnancy (Cat.C): not recommended. |
| Adverse Reactions |
|
Local reactions, irritability, somnolence, fever, crying, GI upset, anorexia. |
| How Supplied |
|
Single-dose vials (0.5mL)—1, 10 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
